Cognitive Outcomes with Sequential Escitalopram Monotherapy and Adjunctive Aripiprazole Treatment in Major Depressive Disorder: A Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report-Reference-Cited by-同舟云学术

Cognitive Outcomes with Sequential Escitalopram Monotherapy and Adjunctive Aripiprazole Treatment in Major Depressive Disorder: A Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report

Published:2021-03 Issue:3 Volume:35 Page:291-304
ISSN:1172-7047
Container-title:CNS Drugs
language:en
Short-container-title:CNS Drugs

Author:

Chakrabarty Trisha^ORCID,McInerney Shane J.,Torres Ivan J.,Frey Benicio N.,Milev Roumen V.,Müller Daniel J.,Rotzinger Susan,Kennedy Sidney H.,Lam Raymond W.,

Funder

Ontario Brain Institute

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Psychiatry and Mental health,Neurology (clinical)

Link

https://link.springer.com/content/pdf/10.1007/s40263-021-00793-1.pdf

Reference48 articles.

1. Rock PL, Roiser JP, Riedel WJ, Blackwell AD. Cognitive impairment in depression: a systematic review and meta-analysis. Psychol Med. 2014;44(10):2029–40.

2. Bora E, Harrison BJ, Yucel M, Pantelis C. Cognitive impairment in euthymic major depressive disorder: a meta-analysis. Psychol Med. 2013;43(10):2017–26.

3. Evans VC, Iverson GL, Yatham LN, Lam RW. The relationship between neurocognitive and psychosocial functioning in major depressive disorder: a systematic review. J Clin Psychiatry. 2014;75(12):1359–70.